Glial cell line-derived neurotrophic factor contributes to delayed inflammatory hyperalgesia in adjuvant rat pain model.
Neurotrophic factors, such as nerve growth factor and brain-derived neurotrophic factor, are members of the structurally related neurotrophin family that play important roles in pain modulation. Although there are also indications for the involvement of glial cell line-derived neurotrophic factor (GDNF), it is unclear whether and how GDNF is involved in inflammatory pain. In the present study, we studied the expression pattern of GDNF in dorsal root ganglia (DRG) and spinal cord, using confocal microscopy. We demonstrate that GDNF is well associated with nonpeptidergic pain pathway and that GDNF could possibly be anterogradely transported from DRG neurons to superficial spinal cord dorsal horn. We also studied the dynamic changes of GDNF expression in rats during chronic inflammation using injection of complete Freund's adjuvant as a model of chronic pain. We found that GDNF was down-regulated in both dorsal root ganglia and spinal cords 2 weeks after arthritis induction. To assess the impact of this down-regulation on pain transmission, we used a function-blocking antibody against GDNF delivered intrathecally in the same chronic-pain animal models. Injection of this antibody to GDNF produced no immediate effect, but decreased the delayed, bilateral hyperalgesia induced from a unilateral injection of complete Freund's adjuvant. The effect of this antibody coincided with the down-regulation of GDNF immunoreactivity in response to inflammation, suggesting that GDNF supports biochemical changes that contribute to hyperalgesia.
Fang
M
M
Neuroscience Research Institute, Peking University Health Science Center, Beijing 100083, PR China.
Wang
Y
Y
He
Q H
QH
Sun
Y X
YX
Deng
L B
LB
Wang
X M
XM
Han
J S
JS
D000704:Analysis of Variance; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001169:Arthritis, Experimental / Q000378:metabolism / Q000503:physiopathology; D015153:Blotting, Western / Q000379:methods; D001835:Body Weight / Q000502:physiology; D004195:Disease Models, Animal; D015536:Down-Regulation; D005260:Female; D005455:Fluorescent Antibody Technique / Q000379:methods; D005620:Freund's Adjuvant / Q000009:adverse effects; D007839:Functional Laterality; D005727:Ganglia, Spinal / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006930:Hyperalgesia / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D037102:Lectins / Q000378:metabolism; D009414:Nerve Growth Factors / Q000378:metabolism*; D020078:Neurogenic Inflammation / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D010146:Pain / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013116:Spinal Cord / Q000033:anatomy & histology / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors
D000906:Antibodies; C495041:Gdnf protein, rat; D051100:Glial Cell Line-Derived Neurotrophic Factor; D037102:Lectins; D009414:Nerve Growth Factors; D005620:Freund's Adjuvant